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ABSTRACT 
In the present work, the thermal behavior of Lornoxicam drug was studied under 
oxidizing (air) and pyrolysis (N2) atmospheres using simultaneous thermogravimetry and 
differential scanning calorimetry (TG-DSC), differential scanning calorimetry (DSC), 
Hot Stage Microscopy (HSM) and Evolved Gas Analysis (EGA) in the form of 
thermogravimetry coupled to infrared spectroscopy (TG-FTIR) and mass spectrometry 
(TG-MS). The thermal degradation product formed at different temperatures were 
examined using liquid chromatography coupled to mass spectrometry (LC–MS) and 
Powder X-Ray Diffraction (PXRD). The thermal study showed that the drug does not 
melt, partially amorphized on heating, it is thermally stable to 205 °C and undergoes 
thermal decomposition in two overlapping mass loss steps. Furthermore, the DSC and 
MS techniques suggest that thermal degradation processes are very complex, which occur 
with the release of gaseous products HCN, SO2, COS, CO2, N2O and CO and formation 
of three intermediate in the thermal residue.  
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1. INTRODUCTION 
Lornoxicam (6-Chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-
thiazine-3-carboxamide 1,1-dioxide, C13H10ClN3O4S2, Fig.1) is a non-steroidal anti-
inflammatory drug (NSAID) that belongs to the “oxicam” class, which presents analgesic, 
anti-inflammatory and antipyretic properties [1,2,3]. It is used in musculoskeletal and 
joint disorders such as osteoarthritis and rheumatoid arthritis. It is also used in the 
treatment of conditions such as postoperative pain and has been demonstrated to be as 
effective as morphine [4]. It is a yellow, amphiprotic crystalline compound with a 
molecular weight of 371.81 g mol-1 that exists as a zwitterion in the solid state [4,5]. 
 
Fig. 1: Chemical structures of Lornoxicam. 
 
 The thermal analysis is widely used by the pharmaceutical industries for quality 
control of drugs because it can provide important information relating to thermal stability, 
degradation and purity determination of drug substances, the physicochemical 
characteristics of natural raw material, crystal forms and polymorphic stability, drug-
excipient compatibility studies, correlation of drug components, among others [6-9]. In 
addition, identifying the thermal degradation products may support studies of forced 
degradation of the drug [10]. Thermal analysis coupled with techniques such as mass 
spectrometry and infrared spectroscopy has been widely used to understand the 
mechanisms of thermal decomposition, allowing the assignment of the products produced 
in the reactions [7-12]. 
The thermal decomposition of Lornoxicam in pyrolytic and oxidative atmosphere 
has been previously reported [5, 13-19]. However, the thermal degradation products have 
not been previously investigated, and the thermal degradation mechanism of this drug is 
unknown. Thus, the main objectives of this study were to conduct a detailed study of the 
thermal behavior in an oxidizing and inert atmosphere and to identify the formed products 
during the thermal decomposition steps. For this, investigations of the thermal behavior 
of Lornoxicam in nitrogen and air atmospheres were undertaken using simultaneous 
thermogravimetry and differential scanning calorimetry (TG–DSC), differential scanning 
calorimetry (DSC), Hot Stage Microscopy (HSM), evolved gas analysis (EGA by TG-
FTIR and TG-MS). The thermal residues from Lornoxicam heated to different 
temperatures (180 °C, 220 °C and 235 °C) were examined using liquid chromatography 
mass-spectrometry (LC–MS) and Powder X-Ray Diffraction (PXRD).   
 
2. MATERIAL AND METHODS 
 
2.1. Materials 
Lornoxicam (99.98% purity) was donated by the Biolab Pharma, São Paulo-
Brazil.  
 
2.2. Thermal Analysis (TA)  
Simultaneous thermogravimetry and differential scanning calorimetry (TG-DSC) 
curves were obtained under dry air and N2 atmospheres with a flow rate of 50 mL min
-1 
using TG-DSC 1 (Mettler-Toledo). Samples weighing about 10 mg were placed in 
alumina crucibles and heated at a rate of 10 ºC min-1 to 800 °C. 
DSC curves were obtained under dry air and N2 atmospheres with a flow rate of 
50 mL min-1 using a DSC Q10 (TA Instruments). Samples weighing about 2 mg were 
sealed in aluminum crucibles with perforated lids and heated at a rate of 10 ºC min-1 to 
225 °C. 
The DSC-microscopy analysis was obtained using a Mettler Toledo DSC 1 stare 
system coupled to an OLYMPUS digital camera, model SC 30, which incorporates a 3.3-
megapixel CMOS sensor and an optical subassembly mechanic Navitar 1-6232D with 6.5 
x zoom. The experimental conditions were similar to those used to obtain the DSC curve. 
The detection of the gaseous products evolved during the thermal decomposition 
was carried out using a TG-DSC 1 (Mettler-Toledo) coupled to a FTIR spectrophotometer 
(Nicolet) with gas cell and DTGS ZnSe detector. The furnace and heated gas cell  
(250 ºC) were coupled through a heated (225 ºC) 120 cm stainless steel transfer line with 
diameter of 3.0 mm with a flow of dry air or N2 at rate of 50 mL min
-1. The FTIR spectra 
were recorded in the 4000-675 cm-1 wavelength range, at a resolution of 4 cm-1 and with 
16 scans per spectrum. The identification of the gaseous products was based on the 
reference spectra available in the spectrometer’s software (OMNIC 8.0) and literature 
data. In addition TG-DSC-FTIR, additional analysis of product gases was undertaken 
with TG-MS. The system was comprised of a SDTATGA1150 (Mettler-Toledo) coupled 
to HPR20 Quadrupole MS (Hiden). Gaseous analytes were transferred from the TG’s 
outlet to the MS’s inlet via a heated capillary line held at 250 °C under separate 
atmospheres of air and nitrogen (60 mL min-1). The mass spectrometer was operated in 
selected ion monitoring mode focusing on key ions apparent in the initial full mass 
screening of lornoxicam. The mass spectrometer was operated in EI mode with the source 
voltage set to 70eV using a SEM detector, an accumulation time of 50 ms was used. 
Samples weighing approximately 5 mg were placed in alumina crucibles and heated 
between 30 and 800 °C at a rate of 10 °Cmin-1. 
Hot-stage microscopy measurements used a HSM-5 (Stanton-Redcroft) coupled 
with stereoscopic microscope (Leica) with a 5 mega pixel digital imager (Celestron) for 
image capture and an optical sensor to measure the reflected light intensity (RLI) 
throughout an experiment. Sample masses of 5 mg were placed in 6 mm alumina crucibles 
and heated at a rate of 10 °C min-1 to 800 °C min-1 under air and nitrogen. 
2.3. LC-MS/MS 
LC-MS/MS analysis were conducted on a 1200 Agilent Technologies LC 
chromatograph coupled to an AB SCIEX Instruments 3200QTRAP mass spectrometer. 
LC separation was achieved using a core shell C-18 reversed phase as the stationary phase 
(150 mm x 4.6 mm, 5µ, from Phenomenex®) and a mixture of water (H2O) and 
acetonitrile (MeCN) containing 0.1% formic acid (v/v) as the mobile phase at  
1 mL.min-1 using a gradient program: 0–0.5 minutes (10% MeCN), 0.5–10 minutes  
(10 –90% MeCN), 10–11 minutes (90% MeCN), 11–11.5 minutes (10% MeCN) and 
11.5–15 minutes (10% MeCN). The injection volume was 20 µL and column temperature 
was 35 °C. 
The intermediate compounds formed during the Lornoxicam degradation were 
determined by LC–MS/MS. MS measurements were operated in a positive mode, with a 
TurboIonSpray® probe. A special software, Lightsight® 2.3 (Nominal Mass Metabolite ID 
Software, AB SCIEX), was used to investigate all possible intermediates. The application 
of the software was performed using the ionization and fragmentation parameters 
optimized for the initial compound; these parameters were obtained by direct infusion at 
a rate of 10 µL min–1 of the standard Lornoxicam solution (500 µg.L-1) in 
water:acetonitrile containing 0.1% of formic acid (1:1, v/v). The MS parameters were: 
curtain gas at 20 psi, ion spray at 5500 V, gases 1 and 2 at 50 psi, temperature of 600 °C, 
declustering potential of 36 V, entrance potential of 7.5 V, and with the interface heater 
turned on. Optimized selected reaction monitoring (SRM) and full-scan experiments were 
automatically performed by the LightSight® 2.3 software. Different kinds of reactions 
were investigated, such as oxidation, hydroxylation, reduction, C-C bond cleavage, and 
others. All MS/MS experiments obtained were combined to fragmentation experiments. 
The LC analysis conditions for the MS measurements were those described earlier. 
The samples used in the LC-MS/MS analysis were obtained using TG-DSC 1 
(Mettler-Toledo). Samples weighing about 10 mg were placed in alumina crucibles and 
heated at a rate of 10 ºC min-1 to different temperatures (180 °C, 220 °C and 235 °C). 
 
 2.4. Powder X-Ray diffraction  
Powder X-Ray Diffraction (PXRD) pattern were obtained by using a MiniFlex 
600 X-ray diffractometer (Rigaku Corporation) employing CuKα radiation (λ = 1.54056 
Å) with setting of 40 kV and 30 mA. The samples were analyzed from 5° to 50° (2θ) with 
10° min−1 and a step size of 0.04. 
The samples preparation for PXRD analysis was similar to that described in the 
topic 2.3. 
 
3. RESULTS AND DISCUSSION 
3.1 TG/DTG-DSC 
The simultaneous TG, DTG and DSC curves of Lornoxicam in dynamic dry air 
and nitrogen atmospheres are shown in Fig. 2 (a and b), respectively. These curves show 
that the drug is thermally stable up to 205 °C (air and N2) and undergoes thermal 
decomposition in two mass loss steps, as suggested by the DTG curve. 
The DTG curve (Fig. 2) suggests that the thermal decomposition mechanism in 
air occurs in more than one stage, as previously seen in the degradation of other oxicam 
drugs [6,20]. In both atmospheres an initially sharp, exothermic, mass loss occurs over 
the range of 205 to 360 °C with a m of 63.02% (air) and 63.97% (N2). This interpretation 
is in disagreement with many previous workers who attributed this thermal event to fusion 
of the drug [15-19]. 
The sample in air undergoes a further mass loss over the range 360 – 680 °C  
(m2 = 38.56%) also with an associated exotherm attributed to complete oxidation of 
remaining material. In contrast, the sample in nitrogen only shows a small, broad, mass 
loss above 360 °C (m2 = 15.34% at 800 °C) without any thermal event in the DSC curve. 
This is attributed to the slow pyrolysis of the solid degradation products produced in the 
first step. 
 
Fig.2: TG/DTG-DSC obtained in air (a) and in N2 (b) atmospheres of Lornoxicam. 
3.2 DSC, DSC-microscopy, HSM and PXRD  
The DSC curves obtained in air and N2 atmospheres are shown in Fig. 3a. These 
curves do not show any significant thermal events up to 200 °C when the onset of the 
exothermic degradation, revealed in the TG-DSC studies, is seen. The DSC curve 
obtained under air atmosphere shows a baseline deviation at approximately 112 ° C, very 
similar to that observed for glassy transitions of amorphous materials [21]. However, this 
does not seem to be the case, since the material is crystalline up to that temperature and 
this effect is not observed in N2 atmosphere, which suggests that this deviation is related 
to experimental issues. In addition, the atmosphere employed does not show any influence 
on the thermal behavior of this compound up to 220 ° C, again in accordance with the 
TG-DSC curves.  
 To investigate any low energy processes that may not be observable using DSC 
the drug was analyzed using DSC-microscopy, HSM and PXRD. HSM and DSC- 
microscopy allow the detection of physical processes through optical changes in the 
sample during heating. Fusion, crystalline transitions, decomposition and others events 
can be observed in the images obtained by HSM [22]. Fig. 3b shows the reflected light 
intensity (RLI) of the drug obtained in air atmosphere plotted as a function of temperature 
with selected micrographs. The RLI curve shows a gradual change in light intensity up to 
170 °C. This corresponds to a clear colour change from yellow to orange as seen in 
associated micrographs A and B. The cause of this process is unknown but there is no 
indication of any fusion. The light intensity falls sharply in the region 170 to 200 °C 
corresponding to a colour change from orange to brown (micrograph C) as the drug 
decomposes. Fig. S1 and S2 presents HSM micrographs obtained in air and nitrogen 
atmospheres. In both atmospheres it was observed that the drug does not melt, as also 
observed in the video (available online) obtained by DSC-microscopy, where it is evident 
that the sample undergoes thermal degradation (browning and material loss) and the 
remaining material becomes liquid. 
 Fig. 3: DSC curve in air and N2 atmospheres (a), RLI graph (b) and PXRD (c) of 
Lornoxicam. 
The PXRD diffractograms of samples heated to different temperatures are shown 
in Fig. 3c. The diffractogram obtained at room temperature (25 °C) shows that the 
acquired drug is crystalline, with no evidence of amorphous content, and corresponds to 
the polymorph II [3]. The diffractogram at 180 °C shows a partial amorphization process, 
indicated by the appearance of a subtle diffraction halo superimposed on the diffraction 
peaks. The sample heated to 220 °C, shows a decrease in crystallinity, when compared to 
Lornoxicam 25 °C, although some peaks are still observed, indicating that the material 
still presents a certain crystallinity resulting from the presence of non-degraded 
Lornoxicam. After heating at 235 °C, the product material has an amorphous character, 
which is attributed to the degradation products formed.  
To better understand what occurs as Lornoxicam is heated, these same residues 
obtained from heating were characterized by LC-MS as discussed in section 3.4. 
 
3.3 Evolved Gas Analyses by TG-FTIR and TG-MS in oxidative and pyrolysis 
conditions 
The TG-FTIR data is shown in Fig. 4. The Gram Schmidt (GS) profiles suggest at 
least two overlapping mass loss steps, in agreement with the TG/DTG curves. The first 
peak is very similar for both atmospheres ((a) air and (b) N2) and is associated with the 
formation of the same gaseous products (CO2, COS, SO2, HCN), suggesting that the 
thermal degradation mechanism is independent of the atmosphere used. However, the GS 
profiles suggest that the second step of mass loss is significantly influenced by the 
atmosphere used, as indicated previously. 
A more detailed inspection of the GS profile of the sample under air shows a small 
peak around 360 °C, the same temperature range of the second peak observed in the GS 
profile for the sample under N2, which suggests that processes similar to those observed 
under pyrolysis conditions are predominant at the beginning of the second mass loss step 
(Fig. 4a, overlapping region), a transition region. However, with increasing temperature, 
the oxidative processes become predominant, which results in the second peak in the GS-
air curve associated with the oxidation of all organic matter present. This can also be 
confirmed by the greater variety and quantity of gaseous products released in this step for 
the sample under air (CO, CO2, N2O, COS, SO2) compared to those released by the 
sample under N2 (CO2 and SO2). 
A detailed analysis was performed of the chemigrams [23] generated from the 
integrated absorbance over specific wavelength ranges intended to show the 
concentration of a particular species present in the accumulated spectra. These 
chemigrams were plotted together with the TG curves (Fig. S3 and S4), which facilitates 
the comparison of the gaseous products released with the mass loss steps. Analysis of the 
results suggests that the first step of thermal decomposition in air atmosphere involves 
the release of CO2, SO2, COS and a small amount of HCN. In the second step it is possible 
to observe the formation of SO2 again along with CO2, probably due to the high 
temperature together with the oxidizing atmosphere, stemming from the decomposition 
of material. In this step, the release of CO and N2O is still observed, however due to low 
intensity the signal of these bands in the spectrum is suppressed by CO2 band. In the 
pyrolytic atmosphere, a lot of CO2 were evolved in the first step of thermal degradation, 
a small amount of HCN, SO2 and COS were observed as well. In the second step only 
COS and a small amount of SO2 were observed as gaseous products. 
 Fig. 4: Gram–Schmidt curve and IR spectra of gaseous products evolved during the 
decomposition of the Lornoxicam in air (a) and N2 (b). 
The mass spectra obtained by TG-MS under oxidizing and pyrolysis conditions 
are shown in Fig. 5. The main gaseous products identified were HCN (m/z 27), CO2 and/or 
N2O (m/z 44), COS (m/z 60) and SO2 (m/z 64). It is interesting to note that in N2 
atmosphere, despite obtaining a fragment with a mass of 44 Da, which could correspond 
to the formation of N2O and/or CO2, the presence of N2O gas was not observed by TG- 
FTIR, which indicates that this signal corresponds only to the release of CO2 from the 
pyrolysis of Lornoxicam. 
In addition, in agreement with the results obtained by TG-FTIR, the first and the 
beginning of the second stage of mass loss is little influenced by the atmosphere used, 
presenting a similar profile of release of gaseous products. On the other hand, with 
increasing temperature, oxidative processes become predominant in air atmosphere, 
leading to a significant increase of CO2 and SO2 release, which is not observed in an inert 
atmosphere, where pyrolysis processes are responsible for the slow loss of mass on the 
TG curve. 
 
Thus, through the comparison of the results obtained by the coupled techniques 
used in this work was possible to distinguish in which step the N2O and the other gaseous 
products are being released during the thermal decomposition. 
 
3.4 LC–MS/MS analysis on intermediate residues from the thermal decomposition in 
oxidative condition of Lornoxicam 
To further understand the mechanism of the Lornoxicam degradation, LC-MS/MS 
was used to analyze the residues of Lornoxicam heated in different temperatures. By 
means of chromatographic separation, the total ion chromatogram (TIC) of Lornoxicam 
before and after heating were obtained as showed in Fig.6. The presence of Lornoxicam 
(MW 371.8 Da) as main peak obtained at 7.3 minutes and m/z 372 ([M+H]+) was observed 
in all chromatograms except for the one referred at temperature of 235 °C (Fig. 1d), where 
other peak could be observed. The comparison of peak area in the chromatogram data 
indicated the degradation of Lornoxicam at 220 and 235 °C (Fig. 7). However, at 180°C 
the Lornoxicam did not undergo decomposition as the peak area remains unchanged. 
 Fig. 6: TIC (total ion chromatogram) (a) unheated; (b) 180 °C; (c) 220 °C and (d) 235°C.  
 Fig. 7: Decomposition of Lornoxicam using the peak area at 7.3 minutes. 
Additional peaks were observed during the LC-MS/MS experiments of samples 
heated at 220 °C and 235 °C, which were not observed in the unheated and 180 °C 
samples. Table 1 shows the main detected intermediate compounds, as well as retention 
times and main fragment ions during thermal degradation. As can be observed three 
intermediate, where two intermediates compounds were obtained at 220 °C instead of one 
in 235 °C, these results confirm the efficiency of decomposition in higher temperatures.  
To elucidate the structure of the products observed at different temperatures, and hence 
propose a decomposition pathway for Lornoxicam, MS/MS experiments were performed. 
The intermediate product detected as m/z 336 (MW 335 Da) indicates a loss of 36 Da, 
when compared to the initial Lornoxicam. This loss suggests the elimination of HCl, 
however it was observed m/z 338 in the same retention time (7.79 minutes) at the 
spectrum data, which  correspond to the isotope M+2 of the chloride (35Cl and 37Cl). Thus, 
the elimination of 36 Da could be associated to the dehydrated product (double loss of 18 
Da (H2O)). The main fragment obtained to the m/z 336 was m/z 121, referred to 
C6H5N2O
+. The ion m/z 121 is the same ion fragment obtained to Lornoxicam as 
mentioned in the Table 1, which confirms that the structure suffered a minimal 
modification and keep the main structure of the Lornoxicam. The intermediate product 
detected as m/z 356 (MW 355 Da) presented m/z 121 as a fragment ion (referred to 
C6H5N2O
+). The loss of 16 Da, when compared to Lornoxicam was associated to the 
formation of a five member ring. Both intermediates were observed at 220 °C. At 235 °C 
only m/z 310 (MW 309 Da) was detected as an intermediate product. The fragment ions 
obtained were m/z 216 (C8H7NO2SCl
+) and 95 (C5H7N2
+). Thus all the proposal structures 
were confirmed by MS/MS experiments performed. The extracted ion chromatograms 
and fragmentation mechanisms for all intermediate products have been shown in 
supplementary Figures S5 and S6. 
Table 1: Intermediate products obtained by LC-MS/MS analyses. 
 
 
4. Conclusions 
Lornoxicam is a thermally stable drug and its initial decomposition temperature is 
not until 205 °C. The thermal decomposition process goes through a two-stage process in 
both oxidant and pyrolytic atmospheres. By means of thermogravimetric techniques 
coupled to FTIR and MS, the investigation of the gaseous products generated during the 
thermal decomposition process under both atmospheric conditions was possible with 
HCN, SO2, COS, CO2, N2O and CO all being observed. Hot-stage microscopy (HSM), 
allowed the visualization of the thermal behavior of Lornoxicam as it was heated and 
gave good agreement with the degradation processes observed using TG. Finally  
LC-MS/MS analysis of the solid residues produced at different temperatures allowed for 
the identification of the various degradation products, which suggests a very complex 
process of thermal decomposition of this drug.  
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